Literature DB >> 19200828

HLA haplotype and supertype associations with cellular immune responses and cytokine production in healthy children after rubella vaccine.

Inna G Ovsyannikova1, Robert A Vierkant, V Shane Pankratz, Megan M O'Byrne, Robert M Jacobson, Gregory A Poland.   

Abstract

Secreted rubella virus-specific cytokines reflect the immunologic mechanisms underlying adoptive immune responses and are significant markers of immunity to rubella. We studied the association between measures of cellular (cytokine and frequency of cytokine-secreted cells) immune responses and HLA haplotypes (with frequencies of > or =1%) and supertypes among 738 healthy children following two doses of rubella vaccine. Haplotype effects were estimated while accounting for linkage phase ambiguity via an expectation maximization algorithm. Importantly, the majority of HLA class I and class II haplotype associations with different cytokines were consistent between Th1, Th2 and/or innate/proinflammatory cytokine groups. We found few class I supertypes (A1, A2, A3, and B7) with potential associations with IL-10 ELISPOT counts and rubella-specific IL-2, IL-10, TNF-alpha, and IL-6 cytokine secretion levels. Our data indicate that the presence or absence of certain HLA haplotypes and/or supertypes may influence the cytokine immune response to rubella vaccine, and represents a more advanced analysis compared to individual candidate gene association studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19200828      PMCID: PMC2693336          DOI: 10.1016/j.vaccine.2009.01.080

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  20 in total

1.  Majority of peptides binding HLA-A*0201 with high affinity crossreact with other A2-supertype molecules.

Authors:  J Sidney; S Southwood; D L Mann; M A Fernandez-Vina; M J Newman; A Sette
Journal:  Hum Immunol       Date:  2001-11       Impact factor: 2.850

2.  Score tests for association between traits and haplotypes when linkage phase is ambiguous.

Authors:  Daniel J Schaid; Charles M Rowland; David E Tines; Robert M Jacobson; Gregory A Poland
Journal:  Am J Hum Genet       Date:  2001-12-27       Impact factor: 11.025

3.  On the advantage of haplotype analysis in the presence of multiple disease susceptibility alleles.

Authors:  Richard W Morris; Norman L Kaplan
Journal:  Genet Epidemiol       Date:  2002-10       Impact factor: 2.135

Review 4.  Epitope-based vaccines: an update on epitope identification, vaccine design and delivery.

Authors:  Alessandro Sette; John Fikes
Journal:  Curr Opin Immunol       Date:  2003-08       Impact factor: 7.486

5.  Immunization with the HBV core 18-27 epitope elicits CTL responses in humans expressing different HLA-A2 supertype molecules.

Authors:  B D Livingston; C Crimi; J Fikes; R W Chesnut; J Sidney; A Sette
Journal:  Hum Immunol       Date:  1999-11       Impact factor: 2.850

6.  Duration of rubella immunity induced by two-dose measles, mumps and rubella (MMR) vaccination. A 15-year follow-up in Finland.

Authors:  I Davidkin; H Peltola; P Leinikki; M Valle
Journal:  Vaccine       Date:  2000-07-15       Impact factor: 3.641

7.  Persistence of rubella antibodies 15 years after subcutaneous administration of Wistar 27/3 strain live attenuated rubella virus vaccine.

Authors:  I B Hillary; A H Griffith
Journal:  Vaccine       Date:  1984-12       Impact factor: 3.641

Review 8.  Personalized vaccines: the emerging field of vaccinomics.

Authors:  Gregory A Poland; Inna G Ovsyannikova; Robert M Jacobson
Journal:  Expert Opin Biol Ther       Date:  2008-11       Impact factor: 4.388

9.  Proportions of Ig classes and subclasses in rubella antibodies.

Authors:  A Sarnesto; S Ranta; P Väänänen; O Mäkelä
Journal:  Scand J Immunol       Date:  1985-03       Impact factor: 3.487

10.  Advantage of rare HLA supertype in HIV disease progression.

Authors:  Elizabeth Trachtenberg; Bette Korber; Cristina Sollars; Thomas B Kepler; Peter T Hraber; Elizabeth Hayes; Robert Funkhouser; Michael Fugate; James Theiler; Yen S Hsu; Kevin Kunstman; Samuel Wu; John Phair; Henry Erlich; Steven Wolinsky
Journal:  Nat Med       Date:  2003-07       Impact factor: 53.440

View more
  12 in total

Review 1.  Vaccinomics: current findings, challenges and novel approaches for vaccine development.

Authors:  Inna G Ovsyannikova; Gregory A Poland
Journal:  AAPS J       Date:  2011-06-14       Impact factor: 4.009

Review 2.  Insights into MHC class I antigen processing gained from large-scale analysis of class I ligands.

Authors:  Gabor Mester; Vanessa Hoffmann; Stefan Stevanović
Journal:  Cell Mol Life Sci       Date:  2011-03-09       Impact factor: 9.261

Review 3.  Factors That Influence the Immune Response to Vaccination.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2019-03-13       Impact factor: 26.132

4.  SNP/haplotype associations in cytokine and cytokine receptor genes and immunity to rubella vaccine.

Authors:  Neelam Dhiman; Iana H Haralambieva; Richard B Kennedy; Robert A Vierkant; Megan M O'Byrne; Inna G Ovsyannikova; Robert M Jacobson; Gregory A Poland
Journal:  Immunogenetics       Date:  2010-03-10       Impact factor: 2.846

5.  Rubella vaccine-induced cellular immunity: evidence of associations with polymorphisms in the Toll-like, vitamin A and D receptors, and innate immune response genes.

Authors:  Inna G Ovsyannikova; Neelam Dhiman; Iana H Haralambieva; Robert A Vierkant; Megan M O'Byrne; Robert M Jacobson; Gregory A Poland
Journal:  Hum Genet       Date:  2009-11-10       Impact factor: 4.132

6.  Human leukocyte antigens and cellular immune responses to anthrax vaccine adsorbed.

Authors:  Inna G Ovsyannikova; V Shane Pankratz; Robert A Vierkant; Nicholas M Pajewski; Conrad P Quinn; Richard A Kaslow; Robert M Jacobson; Gregory A Poland
Journal:  Infect Immun       Date:  2013-05-06       Impact factor: 3.441

7.  HLA genotypes and rubella vaccine immune response: additional evidence.

Authors:  Inna G Ovsyannikova; V Shane Pankratz; Beth R Larrabee; Robert M Jacobson; Gregory A Poland
Journal:  Vaccine       Date:  2014-05-15       Impact factor: 3.641

8.  Genome-wide characterization of transcriptional patterns in high and low antibody responders to rubella vaccination.

Authors:  Iana H Haralambieva; Ann L Oberg; Inna G Ovsyannikova; Richard B Kennedy; Diane E Grill; Sumit Middha; Brian M Bot; Vivian W Wang; David I Smith; Robert M Jacobson; Gregory A Poland
Journal:  PLoS One       Date:  2013-05-01       Impact factor: 3.240

9.  Extended LTA, TNF, LST1 and HLA gene haplotypes and their association with rubella vaccine-induced immunity.

Authors:  Inna G Ovsyannikova; Robert A Vierkant; V Shane Pankratz; Robert M Jacobson; Gregory A Poland
Journal:  PLoS One       Date:  2010-07-27       Impact factor: 3.240

10.  Prediction of IL4 inducing peptides.

Authors:  Sandeep Kumar Dhanda; Sudheer Gupta; Pooja Vir; G P S Raghava
Journal:  Clin Dev Immunol       Date:  2013-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.